Theravance Biopharma (FRA:0TB) Forward Dividend Yield % : 0.00% (As of Jun. 05, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Theravance Biopharma Forward Dividend Yield %?

As of today (2024-06-05), the Forward Annual Dividend Yield of Theravance Biopharma is 0.00%.

As of today (2024-06-05), the Trailing Annual Dividend Yield of Theravance Biopharma is 0.00%.

FRA:0TB's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.665
* Ranked among companies with meaningful Forward Dividend Yield % only.

Theravance Biopharma's Dividends per Share for the three months ended in Mar. 2024 was €0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Theravance Biopharma's Forward Dividend Yield %

For the Biotechnology subindustry, Theravance Biopharma's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Theravance Biopharma's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theravance Biopharma's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Theravance Biopharma's Forward Dividend Yield % falls into.

Theravance Biopharma Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Theravance Biopharma (FRA:0TB) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Theravance Biopharma Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Theravance Biopharma's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Theravance Biopharma (FRA:0TB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theravance Biopharma Inc (FRA:0TB) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

TBPH:USA

Address

Ugland House, South Church Street, George Town, PO Box 309, Grand Cayman, CYM, KY1-1104

Website

https://www.theravance.com

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Theravance Biopharma (FRA:0TB) Headlines

No Headlines